Orexo AB (publ) (STO:ORX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.03B +52.0% |
| Revenue (ttm) | 26.00M -95.6% |
| Net Income | 639.30M |
| EPS | 18.46 |
| Shares Out | 34.51M |
| PE Ratio | 1.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,843 |
| Average Volume | 48,800 |
| Open | 29.45 |
| Previous Close | 29.80 |
| Day's Range | 29.30 - 30.25 |
| 52-Week Range | 12.50 - 43.40 |
| Beta | 0.86 |
| RSI | 49.53 |
| Earnings Date | Feb 5, 2026 |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience
Q4 2025 Orexo AB Earnings Call Transcript
Q4 2025 Orexo AB Earnings Call Transcript
Orexo AB (publ) 2025 Q4 - Results - Earnings Call Presentation
2026-02-05. The following slide deck was published by Orexo AB (publ) in conjunction with their 2025 Q4 earnings call.
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call February 5, 2026 8:00 AM ESTCompany ParticipantsNikolaj Sørensen - President & CEOFrederik Jarrsten -...
Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript
Orexo AB (publ) (OTCQX:ORXOY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Nikolaj Sørensen - President & CEO Frederik Jarrsten - Executive VP & CFO Edward Kim Conference Ca...
Orexo AB (ORXOF) Q3 2025 Earnings Call Highlights: Promising R&D Progress Amidst Market ...
Orexo AB (ORXOF) Q3 2025 Earnings Call Highlights: Promising R&D Progress Amidst Market Challenges
Orexo AB (publ) 2025 Q3 - Results - Earnings Call Presentation
2025-10-23. The following slide deck was published by Orexo AB (publ) in conjunction with their 2025 Q3 earnings call.
Q3 2025 Orexo AB Earnings Call Transcript
Q3 2025 Orexo AB Earnings Call Transcript
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared wi...
Orexo to present clinical data for OX640 at the EAACI Congress
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a ...
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations te...
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.
Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vacci...
Orexo initiates new study of OX640 in participants with allergic rhinitis
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.
Orexo AB reports Q3 results
Orexo´s Nomination Committee for the Annual General Meeting 2025
UPPSALA, Sweden , Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the f...
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
UPPSALA, Sweden , Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Ad...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provi...
Orexo: invitation to presentation of the Q2 2024 Interim Report
UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social...
Report from Orexo AB's annual general meeting, 26 April 2024
UPPSALA, Sweden, April 26, 2024 /PRNewswire/ -- Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nominatio...
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
UPPSALA, Sweden , April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent sp...